Evaluation of the effect of Propolis COVID 19

Evaluation of the effect of Propolis on the recovery process of COVID 19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043279N9

Enrollment

Registered

2020-12-22

Start date

2020-12-05

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Propolis capsules are taken in the form of 500 mg capsules (made by Shahdineh Golha Company) twice a day for 14 days. Intervention 2: Control group: The placebo is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Definitive confirmation of Covid 19 based on RT-PCR results Hospitalized patients Ventilator independent patients

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Type 1 diabetes Severe renal failure Metabolic acidosis Severe respiratory failure Chemotherapy recipients Taking anticoagulants

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Thermometer.;CBC. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Cell Counter.;Cough. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;Muscle pain. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;C Reactive Protein. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Agglutination.;Blood oxygen saturation percentage. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Pulse oximeter.;Respiratory Rate. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: By observing the occurrence of breaths.;Heart Rate. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Pulse oximeter.;Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: ESR device.;Lactate Dehydrogenase. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Autoanalyzer.;CT scan findings. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: CT scan.;Gastrointestinal symptoms. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;Anorexia. Timepoint: At the beginning of the study (before the inter	—

Measure

Time frame

Fever. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Thermometer.;CBC. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Cell Counter.;Cough. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;Muscle pain. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;C Reactive Protein. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Agglutination.;Blood oxygen saturation percentage. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Pulse oximeter.;Respiratory Rate. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: By observing the occurrence of breaths.;Heart Rate. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Pulse oximeter.;Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: ESR device.;Lactate Dehydrogenase. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Autoanalyzer.;CT scan findings. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: CT scan.;Gastrointestinal symptoms. Timepoint: At the beginning of the study (before the intervention), days 3, 5, 7 and after the intervention. Method of measurement: Questionnaire.;Anorexia. Timepoint: At the beginning of the study (before the inter

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Yousefinejad

Sanandaj University of Medical Sciences

hooman56y@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026